Intelligent Bio Solutions Secures 33 New Customer Accounts in the Fiscal 2026 First Quarter, Showing Strong Year-Over-Year Growth and Increasing Total Active Accounts to 480

Rhea-AI Summary

Intelligent Bio Solutions (Nasdaq: INBS) announced it added 33 new customer accounts in fiscal Q1 ended Sept 30, 2025, a 50% year-over-year increase, bringing total active accounts to over 480. Growth concentrated in maritime, transportation & logistics, electrical/electronic manufacturing, construction, and newly entered government administration sectors. About 91% of new accounts were first-time adopters; 9% were expansions. Regional expansion was strongest in the UK with distributor activity across Europe and the Middle East. The company positioned its fingerprint-based non-invasive drug screening to address a projected global market of $17.1B by 2029 (CAGR 15%).

Positive

• 33 new customer accounts in Q1 FY2026
• 50% customer-account growth year-over-year
• Total active accounts increased to over 480
• 91% of Q1 new accounts were first-time adopters
• $17.1B projected global drug-screening market by 2029 (CAGR 15%)

Negative

• None.

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the addition of 33 new customer accounts during its fiscal first quarter for the period ended September 30, 2025, representing a 50% increase compared with the same period the prior year. The continued growth brings the Company’s total number of active accounts to over 480, demonstrating sustained customer expansion and revenue momentum.

Year-over-year analysis, based on full-year figures, highlights the strongest growth in customer acquisition within the maritime, transportation and logistics, electrical and electronic manufacturing, construction, and government administration sectors. Notably, government administration represents a newly entered sector, emphasizing the expanding applicability of INBS's solutions across both public and private domains where operational safety and compliance are critical.

"Our expanding customer base demonstrates increasing confidence in our technology and the growing recognition of its value proposition. As we move toward the second quarter of fiscal year 2026, our focus remains on converting this momentum into sustained revenue growth and long-term value," said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. "Our fingerprint-based drug testing technology is helping organizations streamline screening, minimize downtime, and enhance compliance, delivering measurable operational and economic benefits."

Growth was particularly strong in the United Kingdom, supported by expanding distributor activity across Europe and the Middle East. Approximately 91% of new accounts were first-time adopters of INBS's drug screening solution, while the remaining 9% represented expansion within existing customer organizations, highlighting the Company's ability to attract new users and deepen engagement among its established customer base.

"Adoption is broadening across new and existing customers," said Doug Heath, Vice President of Global Sales at Intelligent Bio Solutions. “More industries are recognizing the operational value of our solution, and existing customers are scaling use as confidence in its accuracy and reliability strengthens."

The global drug screening market is projected to reach USD 17.1 billion by 2029, growing at a CAGR of 15%¹, driven by increasing regulatory focus on workplace safety and a growing demand for non-invasive testing solutions. INBS's continued expansion across high-compliance industries positions the Company to potentially capitalize on this market opportunity and deliver sustainable revenue growth.

The Company's Intelligent Fingerprinting Drug Screening System, which uses fingerprint sweat to provide rapid, hygienic, and non-invasive testing, continues to gain traction as an effective alternative to traditional drug testing methods such as urine and saliva testing. Growing adoption across diverse industries reflects the platform's scalability, reliability, and alignment with modern workforce and compliance standards.

About Intelligent Bio Solutions Inc.   

Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.   

For more information, visit https://ibs.inc/ 

Forward-Looking Statements  

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.  

Company Contact  

Intelligent Bio Solutions Inc.   
info@ibs.inc    
LinkedIn | Twitter   

Investor & Media Contact  

Valter Pinto, Managing Director   
KCSA Strategic Communications   
PH: (212) 896-1254   
INBS@kcsa.com  

---

Hyperlinks and website references in this release are provided for convenience only, and do not incorporate the referenced content into this release.

¹ Research and Markets 2025, Drug Screening Market Report 2025, available at: https://www.researchandmarkets.com/reports/5752023/drug-screening-market-report

FAQ

How many new customer accounts did INBS report for fiscal Q1 2026?

INBS reported 33 new customer accounts for the quarter ended September 30, 2025.

What was INBS's year-over-year customer growth for Q1 2026?

Customer-account growth was 50% year-over-year versus the same period last year.

How many total active accounts does INBS have after Q1 2026 results?

The company reported over 480 total active accounts following Q1 additions.

What share of INBS's new Q1 customers were first-time adopters?

91% of the new accounts in Q1 were first-time adopters of INBS's drug screening solution.

Which sectors drove INBS customer growth in fiscal Q1 2026?

Growth was strongest in maritime, transportation and logistics, electrical and electronic manufacturing, construction, and government administration.

What regional markets supported INBS expansion in Q1 2026?

Expansion was particularly strong in the United Kingdom, supported by distributor activity across Europe and the Middle East.

How does INBS position its technology against market opportunity?

INBS markets its fingerprint-based non-invasive screening as a rapid, hygienic alternative positioned to address a $17.1B global market projected by 2029.